Ionis Pharmaceuticals Inc
F:ISI
Ionis Pharmaceuticals Inc
F:ISI
Price:
64.62
EUR
-3.35%
Market Cap:
€9.4B
Add Note
Add Target
Capture your thoughts and set a target
Decide at what price you'd be comfortable buying and we'll help you stay ready.
Based on
Margin of Safety
0%
10%
20%
30%
40%
50%
Your Price Target
Linked to
current price
· In Buy Zone
Loading
Note attached
Choose the stock you wish to monitor with a price target
Recently Viewed
|
I
|
Ionis Pharmaceuticals Inc
F:ISI
|
US |
|
I
|
Iniziative Bresciane Inbre SpA
MIL:IB
|
IT |
|
Swiss Prime Site AG
SIX:SPSN
|
CH |
|
FirstService Corp
TSX:FSV
|
CA |
|
Jyske Bank A/S
CSE:JYSK
|
DK |
|
S&T Bancorp Inc
NASDAQ:STBA
|
US |
|
Bankinter SA
MAD:BKT
|
ES |
|
Douyu International Holdings Ltd
NASDAQ:DOYU
|
CN |
|
D
|
Deutsche Boerse AG
OTC:DBOEY
|
DE |
|
Schibsted ASA
OSE:VENDB
|
NO |
|
F
|
Fluor Corp
F:FLU
|
US |
|
E
|
Elanco Animal Health Inc
F:5EA
|
US |
|
Alcon AG
NYSE:ALC
|
CH |
|
SEB SA
PAR:SK
|
FR |
|
Tenax Therapeutics Inc
NASDAQ:TENX
|
US |
Reverse DCF
Market Expectations:
Unrealistic
To justify the current price, Netflix Inc. must grow revenue by 36% annually over the next 5 years, which is outside the range of what's considered realistic.
| Revenue Growth Rate | DCF Value | |
|---|---|---|
|
Realistic Range
|
Realistic Low: 10%
|
$601.26
Overvalued by 45%
|
|
Historical: 21%
|
$758.26
Overvalued by 36%
|
|
|
Current DCF: 23%
|
$789.44
Overvalued by 32%
|
|
|
Wall Street: 24%
|
$831.32
Overvalued by 28%
|
|
|
Realistic High: 30%
|
$900.12
Overvalued by 12%
|
|
|
Implied by Price: 36%
|
$977.59
Matches Stock Price
|
Below current price
Above current price
